F. Hoffmann-La Roche Ltd. Market Share Analysis - new company ...- GlobalData's new report, "" provides in-depth information on F. Hoffmann-La Roche Ltd.'s market position in the different medical equipment markets it operates in. The report provides F. Hoffmann-La Roche Ltd. market share information in eight key ... TransWorldNews, 2 weeks ago |
(1) images for "f hoffmann la roche ltd" | ||||
Roche and Ascletis collaborate to develop treatment of HCV in ChinaF. Hoffmann-La Roche Ltd. and Ascletis Inc. have entered into a collaboration to develop and commercialize Roche's investigational drug danoprevir in China for the treatment of Hepatitis-C Virus, or HCV. Under the terms of the agreement, Ascletis ... Individual.com, 3 weeks ago
Roche and Ascletis enter collaboration to advance treatment options for Chinese patients with Hepatitis C
Press Trust, 1 month ago
|
Study Findings on Metabolic Diseases Are Outlined in Reports. . .Study Findings on Metabolic Diseases Are Outlined in Reports from F. Hoffmann-La Roche Metabolic DiseasesNewsRx.com By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Metabolic Diseases. According to news ... Equities.com, 2 months ago
|
Recent Studies from F. Hoffmann-La Roche Add New Data to Med. . .Recent Studies from F. Hoffmann-La Roche Add New Data to Medicinal Chemistry Medicinal ChemistryNewsRx.com By a News Reporter-Staff News Editor at Health & Medicine Week -- New research on Medicinal Chemistry is the subject of a report. According to ... Equities.com, 2 months ago
|
Roche Diagnostics Limited - Medical Equipment - Deals and Alliances Profile - new company profile reportRoche Diagnostics Limited (Roche Diagnostics) undertakes the research, development, manufacture and marketing of diagnostic products for the healthcare markets. It also manufactures research reagents and systems and supplies drugs for cancer and ... TransWorldNews, 1 day ago
Ventana Medical Systems, Inc. - Medical Equipment - Deals and Alliances Profile - new company profile report
TransWorldNews, 2 months ago
|
Results of a Phase I/II Clinical Trial of a New Anti-Malignant Agent, AF802, for ALK-Positive Non-Small Cell Lung Cancer were Published Online on The Lancet OncologyI Chugai Pharmaceutical Co., Ltd. [Main Office: Chuo-ku, Tokyo. Chairman & CEO: Osamu Nagayama (hereafter, Chugai)] announced today that the results of the phase I/II clinical trial of a new anti-malignant agent originated by Chugai, AF802 (Compound ... PipelineReview, 1 week ago
CHUGAI PHARMA -Results of a Phase I/II Clinical Trial of a New Anti-Malignant Agent, AF802, for ALK-Positive Non-Small Cell Lung Cancer were Published Online on 'The Lancet Oncology'
Pharmacy Choice, 1 week ago
|
β-Secretase (BACE1) Inhibitors with High in Vivo Efficacy Suitable for Clinical Evaluation in Alzheimer's Disease Discovery Chemistry, ‡DTA Neuroscience, §Discovery Technologies, Drug Metabolism and Pharmacokinetics, Roche Partnering, F. Hoffmann-La Roche Ltd, pRED, Pharma Research & Early Development, Grenzacherstrasse 124, Basel Journal of Medicinal Chemistry, 2 weeks ago
|
Boehringer-Ingelheim, Roche, Novartis to discuss regulatory challenges occurring in emerging markets for Supply Chain at SMi's Clinical Trial LogisticsEurope's Leading Clinical Trial Logistics to take place in London, UK, 22nd - 23rd May 2013 22nd May 2013: Going forward will be the focus for this year's event where delegates from around the world will hear from leading healthcare professionals on ... PharmiWeb, 1 month ago
|
48 Weeks of Peginterferon Alfa-2a/Ribavirin Improves SVR24 and Decreases Relapse across HCV Genotype 2/3 Patient Subgroups Not Achieving a Rapid Virological Response: N-CORE StudyReported by Jules Levin EASL 2013 Amsterdam April 24-28 T. Berg,1 M.L. Shiffman,2 S. Zeuzem,3 C.P. Berg,4 C. de Figueiredo-Mendes,5 G.J. Dore,6 M. Lucia Ferraz,7 M. Cassia Mendes-Correa,8 M. Patelli Lima,9 E. Parise,7 A.M. Perez Rios,10 T. Reuter,11 ... National AIDS Treatment Advocacy Project, 1 week ago
|
Correlation of IL28B Polymorphism with Degree of Fibrosis: Analysis of Treatment-nave and Treatment-experienced Caucasian Patients Infected with HCV Genotype 1 in the Gen-C StudyReported by Jules Levin EASL 2013 Amsterdam April 24-28 A. Mangia,1 V. de Ledinghen,2 J. Keiss,3 J. Valantinas,4 J. Brahm,5 N. Rasmann,6 D. Messinger,7 F. Tatsch;8 on behalf of the Gen-C study group 1Liver Unit, IRCCS Hospital 'Casa Sollievo della ... National AIDS Treatment Advocacy Project, 1 week ago
|